Amneal Pharmaceuticals Inc (NASDAQ: AMRX)’s stock price has decreased by -0.33 compared to its previous closing price of 9.03. However, the company has seen a 4.53% increase in its stock price over the last five trading sessions. zacks.com reported 2024-11-12 that Amneal (AMRX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company’s fundamentals for clues.
Is It Worth Investing in Amneal Pharmaceuticals Inc (NASDAQ: AMRX) Right Now?
Company’s 36-month beta value is 1.15.Analysts have differing opinions on the stock, with 3 analysts rating it as a “buy,” 1 as “overweight,” 1 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for AMRX is 119.85M, and currently, short sellers hold a 2.92% ratio of that floaft. The average trading volume of AMRX on November 15, 2024 was 1.18M shares.
AMRX’s Market Performance
AMRX stock saw an increase of 4.53% in the past week, with a monthly gain of 3.45% and a quarterly increase of 11.94%. The volatility ratio for the week is 6.61%, and the volatility levels for the last 30 days are 3.58% for Amneal Pharmaceuticals Inc (AMRX). The simple moving average for the past 20 days is 4.54% for AMRX’s stock, with a 27.52% simple moving average for the past 200 days.
Analysts’ Opinion of AMRX
Many brokerage firms have already submitted their reports for AMRX stocks, with JP Morgan repeating the rating for AMRX by listing it as a “Neutral.” The predicted price for AMRX in the upcoming period, according to JP Morgan is $9 based on the research report published on September 06, 2024 of the current year 2024.
RBC Capital Mkts, on the other hand, stated in their research note that they expect to see AMRX reach a price target of $5. The rating they have provided for AMRX stocks is “Sector Perform” according to the report published on April 07th, 2021.
Goldman gave a rating of “Buy” to AMRX, setting the target price at $6.50 in the report published on March 08th of the previous year.
AMRX Trading at 4.94% from the 50-Day Moving Average
After a stumble in the market that brought AMRX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -5.01% of loss for the given period.
Volatility was left at 3.58%, however, over the last 30 days, the volatility rate increased by 6.61%, as shares surge +6.38% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +6.51% upper at present.
During the last 5 trading sessions, AMRX rose by +4.53%, which changed the moving average for the period of 200-days by +68.22% in comparison to the 20-day moving average, which settled at $8.61. In addition, Amneal Pharmaceuticals Inc saw 48.27% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at AMRX starting from BOYER ANDREW S, who sale 40,225 shares at the price of $7.85 back on Aug 15 ’24. After this action, BOYER ANDREW S now owns 256,670 shares of Amneal Pharmaceuticals Inc, valued at $315,766 using the latest closing price.
BOYER ANDREW S, the Executive Vice President of Amneal Pharmaceuticals Inc, sale 22,486 shares at $7.81 during a trade that took place back on Aug 14 ’24, which means that BOYER ANDREW S is holding 296,895 shares at $175,616 based on the most recent closing price.
Stock Fundamentals for AMRX
Current profitability levels for the company are sitting at:
- 0.07 for the present operating margin
- 0.35 for the gross margin
The net margin for Amneal Pharmaceuticals Inc stands at -0.06. The total capital return value is set at 0.08. Equity return is now at value -155.38, with -5.16 for asset returns.
Based on Amneal Pharmaceuticals Inc (AMRX), the company’s capital structure generated 1.04 points at debt to capital in total, while cash flow to debt ratio is standing at 0.07. The debt to equity ratio resting at -26.77. The interest coverage ratio of the stock is 1.5.
Currently, EBITDA for the company is 500.78 million with net debt to EBITDA at 5.72. When we switch over and look at the enterprise to sales, we see a ratio of 1.95. The receivables turnover for the company is 3.58for trailing twelve months and the total asset turnover is 0.77. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.38.
Conclusion
In a nutshell, Amneal Pharmaceuticals Inc (AMRX) has experienced a better performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
